Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Autism Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Autism Overview | 11 | 1 |
| Pipeline Products for Autism Comparative Analysis | 12 | 1 |
| Autism Therapeutics under Development by Companies | 13 | 3 |
| Autism Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Autism Pipeline Products Glance | 17 | 4 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Unknown Stage Products | 20 | 1 |
| Autism Products under Development by Companies | 21 | 2 |
| Autism Products under Investigation by Universities/Institutes | 23 | 1 |
| Autism Companies Involved in Therapeutics Development | 24 | 20 |
| Addex Therapeutics Ltd | 24 | 1 |
| Aequus Pharmaceuticals Inc. | 25 | 1 |
| AgeneBio Inc. | 26 | 1 |
| APeT Holding BV | 27 | 1 |
| BioCrea GmbH | 28 | 1 |
| BrainStorm Cell Therapeutics Inc. | 29 | 1 |
| Cellceutix Corporation | 30 | 1 |
| Confluence Pharmaceuticals LLC | 31 | 1 |
| Coronis Partners Ltd. | 32 | 1 |
| Curemark, LLC | 33 | 1 |
| F. Hoffmann-La Roche Ltd. | 34 | 1 |
| GW Pharmaceuticals Plc | 35 | 1 |
| Heptares Therapeutics Limited | 36 | 1 |
| Intra-Cellular Therapies, Inc. | 37 | 1 |
| MedDay SA | 38 | 1 |
| Omeros Corporation | 39 | 1 |
| Otsuka Holdings Co., Ltd. | 40 | 1 |
| Retrophin Inc. | 41 | 1 |
| Saniona AB | 42 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 43 | 1 |
| Autism Therapeutics Assessment | 44 | 12 |
| Assessment by Monotherapy Products | 44 | 1 |
| Assessment by Combination Products | 45 | 1 |
| Assessment by Target | 46 | 3 |
| Assessment by Mechanism of Action | 49 | 3 |
| Assessment by Route of Administration | 52 | 2 |
| Assessment by Molecule Type | 54 | 2 |
| Drug Profiles | 56 | 67 |
| (dextromethorphan + quinidine sulfate) Drug Profile | 56 | 5 |
| acamprosate calcium Drug Profile | 61 | 1 |
| ACT-01 Drug Profile | 62 | 1 |
| ADX-71441 Drug Profile | 63 | 3 |
| ADX-88178 Drug Profile | 66 | 2 |
| aripiprazole Drug Profile | 68 | 4 |
| aripiprazole Drug Profile | 72 | 2 |
| carbetocin Drug Profile | 74 | 1 |
| CB-0306 Drug Profile | 75 | 1 |
| CM-AT Drug Profile | 76 | 2 |
| Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome Drug Profile | 78 | 1 |
| GWP-42006 Drug Profile | 79 | 2 |
| histamine dihydrochloride Drug Profile | 81 | 1 |
| HTL-14242 Drug Profile | 82 | 1 |
| ITI-007 Drug Profile | 83 | 8 |
| KM-391 Drug Profile | 91 | 1 |
| lurasidone hydrochloride Drug Profile | 92 | 7 |
| MD-1103 Drug Profile | 99 | 1 |
| niacinamide CR Drug Profile | 100 | 1 |
| NurOwn Drug Profile | 101 | 9 |
| oxytocin Drug Profile | 110 | 1 |
| RG-7314 Drug Profile | 111 | 1 |
| SF-999 Drug Profile | 112 | 1 |
| Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism Drug Profile | 113 | 1 |
| Small Molecule to Agonize GABRA5 Receptor for CNS Disorders Drug Profile | 114 | 1 |
| Small Molecule to Block Chloride Channels for Autism Drug Profile | 115 | 1 |
| Small Molecule to Target GPR63 for Autism Drug Profile | 116 | 1 |
| Small Molecule to Target Oxytocin for Autism and Anxiety Disorders Drug Profile | 117 | 1 |
| Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism Drug Profile | 118 | 1 |
| Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome Drug Profile | 119 | 1 |
| Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology Drug Profile | 120 | 1 |
| Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure Drug Profile | 121 | 1 |
| Synthetic Peptide for Autism and Alzheimer's Disease Drug Profile | 122 | 1 |
| Autism Dormant Projects | 123 | 3 |
| Autism Discontinued Products | 126 | 1 |
| Autism Product Development Milestones | 127 | 6 |
| Featured News &Press Releases | 127 | 1 |
| Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch | 127 | 1 |
| Dec 07, 2015: Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism | 127 | 1 |
| Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole | 128 | 1 |
| May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism | 128 | 1 |
| Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment | 129 | 1 |
| Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt | 129 | 1 |
| Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis | 129 | 1 |
| Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz | 130 | 1 |
| Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism | 130 | 1 |
| Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors | 130 | 1 |
| Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism | 131 | 1 |
| May 31, 2012: Study Reports New Treatment For Irritability In Autism | 131 | 1 |
| Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism | 132 | 1 |
| Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism | 132 | 1 |
| Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation | 132 | 1 |
| Appendix | 133 | 2 |
| Methodology | 133 | 1 |
| Coverage | 133 | 1 |
| Secondary Research | 133 | 1 |
| Primary Research | 133 | 1 |
| Expert Panel Validation | 133 | 1 |
| Contact Us | 133 | 1 |
| Disclaimer | 134 | 1 |